Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Prukkanone, Benjamas ^a   Vos, Theo ^a   Burgess, Philip ^a   Chaiyakunapruk, Nathorn ^b   Bertram, Melanie ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NARESUAN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TIANEPTINE; TRAZODONE; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; THAILAND; COMPARATIVE STUDY; INTERNATIONAL CLASSIFICATION OF DISEASES; MENTAL HOSPITAL; MIDDLE AGED; PSYCHOLOGICAL ASPECT; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HOSPITALS, PSYCHIATRIC; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; THAILAND;

EID: 77955753628     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-64     Document Type: Article

References (27)

1. The Thai Working Group on Burden of Disease and Injuries Burden of Disease and Injuries in Thailand; Priority setting for policy 2002, Nonthaburi: Printing House of The War Veterans Organization of Thailand Under Royal Potronage of his Majesty the King, The Thai Working Group on Burden of Disease and Injuries.
2. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD. Multiple Recurrences of Major Depressive Disorder. American Journal of Psychiatry 2000, 157(2):229. 10.1176/appi.ajp.157.2.229, 10671391.
3. Sadock BJ, Virginia A. Comprehensive text book of Psychiatry. 2005, 2. Baltimore: Williams & Wilkins, Kaplan HI, Sadock BJ.
4. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J. Beliefs About Antidepressant Medications in Primary Care Patients Relationship to Self-Reported Adherence. Med Care 2005, 43:1203-1207. 10.1097/01.mlr.0000185733.30697.f6, 16299431.
5. White TJ, Vanderplas A, Ory C, Dezii CM, Chang E. Economic Impact of Patient Adherence with Antidepressant Therapy Within a Managed Care Organization. Disease Management and Health Outcomes 2003, 11(12):817.
6. Sheehan DV, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the Economic Consequences of Early Antidepressant Treatment Discontinuation: A Comparison Between Controlled-Release and Immediate-Release Paroxetine. Journal of Clinical Psychopharmacology 2004, 24(5):544. 10.1097/01.jcp.0000140999.45053.07, 15349013.
7. Wipisamakul S, Chulakadabba S, Charatchrungwitaya S, Wanachavee U. A Study of Antidepressant Prescription in Major Depressive Disorders in the Out- Patient Psychiatric Department of Siriraj Hospital. Siriraj Med J 2005, 57:328-335.
8. Department of Mental Health MoPH, Thailand Guidebook of Depressive Disorders Surveillance and Care: Provincial level 2008, Ubonrajthani province, 2, Department of Mental Health MoPH, Thailand.
9. Karasu TB, . American Psychiatric A Practice Guideline for the Treatment of Patients with Major Depressive Disorder (revision): Work Group on Major Depressive Disorder 2000, American Psychiatric Association, American Psychiatric A.
10. Osterberg L, Blaschke T, Koop CE. Adherence to Medication. N Engl J Med 2005, 353:487-497. 10.1056/NEJMra050100, 16079372.
11. DiMatteo MR, Haskard KB. Further challenges in adherence research: measurements, methodologies, and mental health care. Med Care 2006, 44(4):297-299. 10.1097/01.mlr.0000214527.98190.2a, 16565628.
12. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006, 44(4):300-303. 10.1097/01.mlr.0000204287.82701.9b, 16565629.
13. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures. The Annals of Pharmacotherapy 2006, 40(7):1280. 10.1345/aph.1H018, 16868217.
14. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15(8):565-574. 10.1002/pds.1230, 16514590.
15. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. Journal of Clinical Epidemiology 1997, 50(1):105-116. 10.1016/S0895-4356(96)00268-5, 9048695.
16. White TJ, Chang E, Leslie S, Gilderman A, Berenbeim DM, Dezii CM, Melikian C. Patient Adherence with HMG Reductase Inhibitor Therapy among Users of Two Types of Prescription Services. Journal of Managed Care Pharmacy 2002, 8(3):186-191.
17. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatrica Scandinavica 2000, 101(2):119-124. 10.1034/j.1600-0447.2000.90061.x, 10706011.
18. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Poor Antipsychotic Adherence Among Patients With Schizophrenia: Medication and Patient Factors. Schizophrenia Bulletin 2004, 30(2):255.
19. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clinical Therapeutics 1999, 21(6):1074-1090. 10.1016/S0149-2918(99)80026-5, 10440628.
20. Woltmann EM, Valenstein M, Welsh DE, Lee TA, Wolschon PA, Grabowski J, Reilly PA. Using Pharmacy Data on Partial Adherence to Inform Clinical Care of Patients With Serious Mental Illness. Psychiatric Services 2007, 58(6):864. 10.1176/appi.ps.58.6.864, 17535949.
21. Keene MS, Eaddy MT, Nelson WW, Sarnes MW. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care 2005, 11(12 Suppl):S362-369.
22. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. British Medical Journal 2003, 326:1014. Br Med Assoc, 10.1136/bmj.326.7397.1014, 154760, 12742924.
23. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. British Medical Journal 1995, 310(6992):1433-1438. 2549813, 7613276.
24. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. The British Journal of Psychiatry 1997, 170(2):120. 10.1192/bjp.170.2.120, 9093499.
25. Pridmore S, Turnier-Shea Y. Medication options in the treatment of treatment-resistant depression. Australian & New Zealand Journal of Psychiatry 2004, 38(4):219.
26. Horgan D. A survey of combination antidepressant use in Australia. Australasian Psychiatry 2007, 15(1):26-29. 10.1080/10398560601109855, 17464630.
27. Rishi S, Fang X, Ronald EA. Estimating Medication Persistency Using Administrative Claims Data. Am J Manag Care 2005, 11:449-457.